234 related articles for article (PubMed ID: 24496038)
1. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Moody TW; Chan DC; Mantey SA; Moreno P; Jensen RT
Life Sci; 2014 Mar; 100(1):25-34. PubMed ID: 24496038
[TBL] [Abstract][Full Text] [Related]
2. Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3.
Moody TW; Ramos-Alvarez I; Jensen RT
Peptides; 2022 Oct; 156():170858. PubMed ID: 35932909
[TBL] [Abstract][Full Text] [Related]
3. Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner.
Moody TW; Lee L; Ramos-Alvarez I; Jensen RT
Eur J Pharmacol; 2019 Dec; 865():172735. PubMed ID: 31614143
[TBL] [Abstract][Full Text] [Related]
4. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
5. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
6. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
7. Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.
Moody TW; Sancho V; di Florio A; Nuche-Berenguer B; Mantey S; Jensen RT
Peptides; 2011 Aug; 32(8):1677-84. PubMed ID: 21712056
[TBL] [Abstract][Full Text] [Related]
8. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.
Moody TW; Berna MJ; Mantey S; Sancho V; Ridnour L; Wink DA; Chan D; Giaccone G; Jensen RT
Eur J Pharmacol; 2010 Jul; 637(1-3):38-45. PubMed ID: 20388507
[TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.
Moody TW; Osefo N; Nuche-Berenguer B; Ridnour L; Wink D; Jensen RT
J Pharmacol Exp Ther; 2012 Jun; 341(3):873-81. PubMed ID: 22389426
[TBL] [Abstract][Full Text] [Related]
10. CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.
Moody TW; Nuche-Berenguer B; Moreno P; Jensen RT
J Mol Neurosci; 2015 Jul; 56(3):663-72. PubMed ID: 25761747
[TBL] [Abstract][Full Text] [Related]
11. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
Moody TW; Ramos-Alvarez I; Moreno P; Mantey SA; Ridnour L; Wink D; Jensen RT
Peptides; 2017 Apr; 90():90-99. PubMed ID: 28153500
[TBL] [Abstract][Full Text] [Related]
12. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.
Zhang Y; Zhu S; Yi L; Liu Y; Cui H
Mol Cell Biochem; 2014 Apr; 389(1-2):1-8. PubMed ID: 24357116
[TBL] [Abstract][Full Text] [Related]
13. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
14. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
[TBL] [Abstract][Full Text] [Related]
15. Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth.
Tokumoto H; Setoguchi T; Saitoh Y; Sasaki H; Nagano S; Maeda S; Tanimoto A; Taniguchi N
Mol Carcinog; 2019 Dec; 58(12):2230-2240. PubMed ID: 31478563
[TBL] [Abstract][Full Text] [Related]
16. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
[TBL] [Abstract][Full Text] [Related]
17. RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells.
Liao WL; Lin H; Li YH; Yang TY; Chen MC
Am J Physiol Cell Physiol; 2023 Nov; 325(5):C1313-C1325. PubMed ID: 37746694
[TBL] [Abstract][Full Text] [Related]
18. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
[TBL] [Abstract][Full Text] [Related]
19. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
20. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
